To evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NG) as a first-line
treatment for advanced pancreatic cancer. A meta-analysis was performed to assess the …

BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem+ nabPTX) were
recently introduced for metastatic pancreatic cancer treatment. However, studies that …

Background The prognosis of pancreatic cancer (PC) has been improved by new
chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and …

Aim Chemotherapy‐induced peripheral neuropathy (CIPN) is a major toxicity limiting the use
of nab‐paclitaxel (Nab‐P) in treating patients with pancreatic cancer. The aim of this study …

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most
frequent adverse events observed with taxane use, whose disability often required …

This study aimed to evaluate gemcitabine (GEM)/paclitaxel (PTX) co-loaded into a lecithin-
based self-nanoemulsifying preconcentrate (LB SNEP) orally administered in a metronomic …

Background/Aims Controversy regarding the effectiveness of neoadjuvant therapy for
resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify …

Background This head-to-head study compared a 3-week versus 4-week schedule of nab-
paclitaxel in patients with metastatic breast cancer (mBC). Methods Patients with HER2 …

Purpose FOLFIRINOX is the standard therapy in patients with unresectable pancreatic
cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and …

Objectives: Limited evidence exists for chemotherapy selection in advanced pancreatic
cancer (APC) after first-line FOLFIRINOX. Second-line gemcitabine/nab-paclitaxel …